Abstract: The present invention provides nucleic acid and amino acid sequence of the novel I-1 and I-2 polypeptides, which are associated with human inflammatory bowel disease (IBD). Methods of diagnosing and treating inflammatory bowel disease using the IBD-associated I-1 and I-2 antigens also are provided.

Abstract: A method of producing active immunity against a viral disease in an animal subject comprises administering to the subject a vaccine conjugate consisting essentially of a live virus and a neutralizing factor bound to the live virus. The neutralizing factor is selected from the group consisting of antibodies and antibody fragments. The live virus is one capable of producing disease in the subject, and the antibody or antibody fragment is one capable of neutralizing the live virus. Preferred subjects are birds, a preferred virus is Infectious Bursal Disease Virus, and a preferred route of administration to birds is by in ovo administration.

Abstract: This invention relates to novel peptides and proteins and nucleic acids encoding them, which are useful against HIV infection. The peptides comprise an amino acid sequence of a part of the HIV-1 p17 protein or of the HIV-2 p16 protein, from amino acid residues 31 to 45 or from amino acid residues 41 to 55. The proteins are recombinant p16 and p17 proteins having an alteration in helix A which is defined by amino acid residues 31 to 46, or the A-B loop which is defined by amino acid residues 47 to 52.

Abstract: The present invention relates, in general, to AAMP-1, and to a peptide derived from the amino-terminal region of AAMP, P189. In particular, the present invention relates to a DNA segment encoding AAMP-1, P189 or fragments thereof; polypeptides encoded by said DNA segment; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing a AAMP-1, and P189 polypeptide or fragments thereof; antibodies specific to AAMP-1; and a method of measuring the amount of AAMP-1 in a sample. The present invention further relates to methods of using AAMP, P189 or fragments thereof in promoting cell-cell or cell-substrate adhesion, wound healing in patients, prosthetic acceptance, concentrating heparin in tissues, and inhibiting metastases and invasion of malignant cells.

Abstract: A process for detecting HIV infection, Hepatitis A, B and C, and other similar infections in a plasma sample, wherein the process involves the use of an excitation laser source to irradiate upon the plasma sample an excitation laser beam to obtain a fluorescence emission spectrum of the plasma sample. The invention uses an excitation laser wavelength of about 355 nanometers. Detection of the fluorescence is made in the wavelength range from about 380 to 600 nanometers. The resulting spectrum of the sample is compared with the spectrum of a control which is free from infection. Analysis of the parameters of the emission spectra including, but not limited to, peak intensity wavelength, amplitude at the peak intensity, area ratio of left and right portions of the emission spectra, and shifts of the peak intensity wavelength, allows determination of HIV infection, Hepatitis A, B and C, and other similar infection in the plasma.

Abstract: The present invention provides two new HIV/SIV translocation promoting agents, Bonzo and BOB. The present invention also provides the amino acid and DNA sequences of human, African green monkey, and pigtail macaque of the receptor protein Bonzo. Mammalian cells transfected with Bonzo and/or BOB and human CD4 as well as antibodies to the receptor Bonzo are also included. Furthermore, a method of identifying other such translocation promoting agents is also disclosed. Diagnostic and therapeutic uses of the translocation promoting agents of the present invention are also provided.

Abstract: Three new HIV-1 isolates HIV-1 D747(ECACC V92082718), HIV-1 D757(ECACC V92082719) and HIV-1 D760(ECACC V92082720) are disclosed, which represent a further independent subtype of the HIV-1 family and have been recovered from Indian patients which at the time when the virus was isolated showed no typical AIDS symptoms. Also disclosed are vaccines against HIV-1 infections by this subtype and a process for producing the same, as well as the use of the HIV-1 infection, as well as for differential diagnosis.

Abstract: A method of producing active immunity against a viral disease in an animal subject comprises administering to the subject a vaccine conjugate consisting essentially of a live virus and a neutralizing factor bound to the live virus. The neutralizing factor is selected from the group consisting of antibodies and antibody fragments. The live virus is one capable of producing disease in the subject, and the antibody or antibody fragment is one capable of neutralizing the live virus. Preferred subjects are birds, a preferred virus is Infectious Bursal Disease Virus, and a preferred route of administration to birds is by in ovo administration.

Abstract: Disclosed is a substantially pure HIV antigen comprising a Gag-Env fusion otein consisting of a Gag peptide fused at its C-terminus to an Env peptide, wherein the Gag peptide comprises a contiguous sequence of at least ten amino acids of the amino acid sequence represented by Gag (308-437) and the Env peptide comprises a contiguous sequence of at least a part of the amino acid sequence represented by Env (512-699), the part containing at least one epitope which is reactive to an HIV antibody. The gag-env fusion DNA corresponding to the HIV antigen of the present invention allows the production of the desired high antigenicity HIV antigen in high yield. Therefore, the HIV antigen of the present invention can be advantageously used as an active component for a diagnostic reagent, a vaccine, an antibody preparation and a therapeutic reagent for AIDS. Also disclosed is a substantially pure HIV antigen comprising a Gag protein SEQ ID No.:1 coded for by the entire gag gene.

Abstract: The instant invention provides for isolated gp48 glycoprotein, methods of passive immunization with anti-gp48 antibodies, and methods of active immunization for generating anti-gp48 antibodies.

Abstract: Prolonged cold storage of red blood cells by oxygen removal and additive usage. A cost-effective, 4.degree. C. storage procedure that preserves red cell quality and prolongs post-transfusion in vivo survival is described. The improved in vivo survival and the preservation of adenosine triphosphate levels, along with reduction in hemolysis and membrane vesicle production of red blood cells stored at 4.degree. C. for prolonged periods of time, is achieved by reducing the oxygen level therein at the time of storage; in particular, by flushing the cells with an inert gas, and storing them in an aqueous solution which includes adenine, dextrose, mannitol, citrate ion, and dihydrogen phosphate ion, but no sodium chloride, in an oxygen-permeable container which is located in an oxygen-free environment containing oxygen-scavenging materials.

Abstract: A method for measuring the responses of sets or subsets of lymphocytes to mitogens or antigens in a sample is disclosed comprising incubating a population of cells with a mitogen or antigen, separating the desired subset of cells by means of the interaction of a specific binding reagent that is attached to the solid phase with a cell surface determinant that is present on the cell subset of interest, lysing the separated cells, and measuring an intracellular component that is increased if the cells have responded to the stimulus. The method provides a convenient, simple, and reliable method for measuring immune function in a variety of conditions.

Abstract: Methods for forming thin layer barrier layer films for use in enzyme containing laminated membranes and membranes formed thereby are disclosed. The barrier layers exhibit improved acetaminophen rejection and comprise a cellulose acetate/cellulose acetate butyrate blend. The thin layer barrier membranes are formed from a plural solvent containing solution and are cured at a critical temperature of about 102.degree.-114.degree. F., most preferably at about 106.degree. F.-114.degree. F. while traveling through a circulating hot air oven. Alternatively, the membranes can be cured at room temperature or in a stagnant oven at temperatures of from room temperature to about 175.degree. C. (350.degree. F.) for a period of from about 10 minutes to 1 hour.

Abstract: Quantitative immunochromatographic assays for measuring the amount of an analyte, and an apparatus for use in the assays, are disclosed. The assays involve obtaining a fluid sample which contains the analyte; supplying a RAMP.TM. apparatus which includes a membrane having an application point, a detection zone, and a contact region, where the contact region is between the application point and the detection zone, and has antibody-coated particles imbedded within it; contacting the application point with the fluid sample; maintaining the RAMP.TM.

Abstract: A substitute oral fluid standard for testing, calibration, and standardization of devices and methods for collection, storage, and analysis of oral fluids. The oral fluid standard comprises a mucin and a protease inhibitor.

Abstract: A peptide of up to about 40 amino acids including the core sequence inclusive of amino acids at positions 92-109 of the p17 gag core protein of HIV-1, such as, Ile-Y.sub.1 -Y.sub.2 -Lys-Asp-Thr-Lys-Glu-Ala-Leu-Y.sub.3 -Lys-Ile-Glu-Glu-Glu-Gln-AsnwhereinY.sub.1 is Asp or Glu,Y.sub.2 is Val or Ile, andY.sub.3 is Glu or Asp,is effective in inhibiting replication of the HIV virus and provides the basis for a vaccine for treatment or prevention of AIDS.

Abstract: A substitute saliva standard for use in testing, calibration, and standardization of devices and methods for collecting and analyzing oral fluids.

Abstract: The present invention is concerned with a new strain of Mareks Disease Virus and to a vaccine for the protection of poultry against Mareks Disease containing the novel strain. The invention also relates to bivalent or polyvalent vaccines comprising in addition other viruses of the Mareks Disease virus group, i.e. HVT.